An Open-label, Extension Study, to Investigate the Long-term Safety and Tolerability of Cannabis Based Medicine Extracts in Patients With Cancer-related Pain.

NCT00675948 Phase 3 COMPLETED Results posted

The purpose of this study is to assess the safety and tolerability of long term therapy with Sativex® and GW-2000-02.

Details

Lead sponsor	Jazz Pharmaceuticals
Phase	Phase 3
Status	COMPLETED
Enrolment	43
Start date	2002-04
Completion	2006-09

Conditions

• Pain
• Cancer

Interventions

• Sativex
• GW-2000-02

Primary outcomes

• The Incidence of Adverse Events as a Measure of Subject Safety — 0 - 657 days
  The number of subjects who experienced an adverse event in this study is presented.

Countries

United Kingdom